In a recent phase II study, a time-limited, chemotherapy-free regimen guided by MRD monitoring achieved deep and durable responses in patients with previously untreated #MantleCellLymphoma #MCL, with CRs of 67% and 90% achieved in the studied cohorts: https://ow.ly/nf1V50YoEER
#HemeSky #MedSky

Magda Szubanski in remission after stage 4 cancer treatment The Australian entertainer reveals she is in remission after completing chemotherapy treatment for stage 4 blood cancer.

Oh happy news 😊. Along with the rest of Australia & beyond, keeping the beloved Magda Szubanski in my thoughts. The number of times she has made us all cry with laughter, the very least we can do is this. Thank you science #MantleCellLymphoma #MedicalResearchMatters

www.abc.net.au/news/2026-02...

BTK Inhibitor Therapy Makes Inroads Into First-Line MCL BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

Tycel J. Phillips, MD, of @cityofhope.bsky.social elucidates the research landscape of BTKis in #MCL, particularly its potential as a first-line treatment.

https://bit.ly/3ZiPcRy

#MantleCellLymphoma #lymsm

New video · Monday, Jan 12 🎬 Tap to view!

Eight years ago, 2018. Two sweet dogs gone. Newly diagnosed #MantleCellLymphoma
Still on #WatchAndWait #NoTreatment
Eight years later my health is good, but the protests continue. #SaveOurDemocracy
#ColumbusOhio

SENP3 Promotes Mantle Cell Lymphoma Development through Regulating Wnt10a Expression

This study shows #SENP3 upregulation drives #MantleCellLymphoma progression—its knockdown inhibits proliferation, induces #apoptosis, suppresses Wnt/Wnt10a signaling, and limits #tumor growth, highlighting SENP3 as a promising #TherapeuticTarget.
Read: doi.org/10.1007/s115...

Sonrotoclax Gets Priority Review for R/R Mantle Cell Lymphoma A next-generation BCL2 inhibitor, sonrotoclax, receives FDA Priority Review for previously treated relapsed or refractory mantle cell lymphoma.

The @fda.gov has granted Priority Review to the NDA for sonrotoclax for the treatment for patients with R/R #mantleCellLymphoma, following treatment with a BTK inhibitor. From @medicalprofref.bsky.social.

https://bit.ly/3XxY9pq

#lymsm

#Lymphopoiesiscont36 #NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations #MedicalInfographic #Histopathology #MedicalLearning #MedStudent #Pathology

#Lymphopoiesiscont36
#NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations

In a fantastic discussion from #iwNHL25, Stephen Ansell, Michael Wang & Tycel Phillips provide updates on the management of #MantleCellLymphoma. The experts discuss frontline therapy, the evolving role of autoSCT, treatment sequencing, & the value of MRD.

Watch here:
👉 buff.ly/oAIf6YW 👈

#LYMsm

Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:

👉 buff.ly/aDN40ud 👈

#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky

This study shows that SENP3, a SUMO-specific protease, is upregulated in #MantleCellLymphoma (MCL) & silencing it deregulates Wnt10a, slows cell growth & promotes #Apoptosis, making it a potential #biomarker & #therapeutic target for MCL. #medsky
Read:
link.springer.com/article/10.1...

Synapse: Your Connection to our MSK Authors
Meet: Ashlee Joseph
Research Focus: Medicine; Research Project Associate

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma

synapse.mskcc.org/synapse/work...

#MantleCellLymphoma

Sonrotoclax Hits Primary End Point in Phase 1/2 Trial of Relapsed/Refractory MCL A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

Sonrotoclax Hits Primary End Point in Phase 1/2 Trial of Relapsed/Refractory MCL
#MantleCellLymphoma #lymsm #hematology
www.onclive.com/view/sonroto...

Hear as Elizabeth Budde of @cityofhope.bsky.social shares the promising results of a Phase II study evaluating mosunetuzumab plus polatuzumab vedotin in pts with R/R #MantleCellLymphoma & high-risk features.

Click here:
🎥 buff.ly/lq9B4hr

#LYMsm #18ICML #CTSM #TrialUpdate #ImmunoOnc #BloodSky

Following #18ICML, we had the pleasure of catching up with Nilanjan Ghosh to hear his highlights in #NonHodgkinLymphoma from this year’s meeting.🩸

Click here for the comprehensive overview:
👉 buff.ly/RQDPS8G

#DLBCL #MantleCellLymphoma #FollicularLymphoma #LYMsm #CTSM #Lymphoma #ImmunoOnc

Sonrotoclax Plus Zanubrutinib Generates Durable Responses in R/R #MantleCellLymphoma #MCL
www.onclive.com/view/sonroto...

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible #MCL
#MantleCellLymphoma #lymsm
www.onclive.com/view/europea...

NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

#NICE #EliLilly #Omvoh #Crohnsdisease #BeOneMedicine #Brukinsa #mantlecelllymphoma #ulcerativecolitis #NICEguidance #gastroenterology #SMC #Brukinsa #relapsedMCL #refractoryMCL #Waldenstromsmacroglobulinaemia #chroniclymphocyticleukaemia #marginalzonelymphoma
pharmaphorum.com/news/nice-ba...

Two new medicines have been cleared for routine use by the #NHS in England and Wales – #EliLilly's Omvoh for #Crohnsdisease and #BeOne Medicine's Brukinsa for #mantlecelllymphoma.

pharmaphorum.com/news/nice-ba...

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma
Advani, R. H., Ali, R. et al.
Paper
Details
#FunctionalGenomics #TumorMicroenvironment #MantleCellLymphoma

#18ICML | Watch our interview with David Lewis of @plymuni.bsky.social‬, who discusses an analysis of MRD data from the ENRICH trial, a PhIII trial comparing ibrutinib-rituximab vs R-chemotherapy in frontline #MantleCellLymphoma:

👉 buff.ly/qB2G9RG

#LYMsm #HemOnc #CTSM #ICML2025 #BloodSky

The GOlDiLOX trial is investigating the combination of pirtobrutinib + glofitamab in #MantleCellLymphoma that progresses after covalent BTKis.🩸

Want to learn more? Watch our interview with @drmikedickinson.bsky.social from #EHA2025:

🎥 buff.ly/FL2519k

#LYMsm #CTSM #BloodSky #HemeSky #TrialUpdate

MAIC Analysis Reveals Long-Term PFS Benefit With Zanubrutinib Over Orelabrutinib in R/R MCL
#MantleCellLymphoma #MCL
www.onclive.com/view/maic-an...

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL
#MCL #lymsm #MantleCellLymphoma
www.onclive.com/view/large-c...

Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL
#MantleCellLymphoma #MCL
www.onclive.com/view/pooled-...

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma PURPOSEMantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR)...

💡 This study highlights on-site adaptive CAR T manufacturing as a safe, efficient, and highly effective approach for MCL. Future research will determine long-term durability! 🔄🔍

manuscript: ascopubs.org/doi/10.1200/...

#CAR_T #MantleCellLymphoma #Immunotherapy #CancerResearch

#ASH24 | Ingrid Glimelius discusses the safety and efficacy of zilovertamab vedotin in R/R #MantleCellLymphoma post-BTK inhibitor treatment.

Check out the interview here:

👉 https://buff.ly/3CAZoxg 👈

#LYMsm #ImmunoOnc #Lymphoma #HemOnc

Hear the updates in #MantleCellLymphoma from #ASH24 and key takeaways for community oncologists in our wonderful interview with @krishpatelmd.bsky.social of @scrinetwork.bsky.social!

Click here to watch:
👉 buff.ly/4jmisjj 👈

#LYMsm #CTSM #HemOnc #HemeSky @ash.hematology.org

Happening now: Presentation by Dr. M. Lia Paloma on #mantlecelllymphoma. @ash-hematology.bsky.social #ASH24

At #ASH24, Dr. M. Lia Palomba will lead an education session on T cell-based therapies for treating relapsed or refractory #MantleCellLymphoma. @mskcancercenter.bsky.social.

10:30 a.m. PST
https://buff.ly/4ikSPit

What is Mantle Cell Lymphoma and Its Treatment with Acalabrutinib Buy Acalabrutinib capsules from The Indian Pharma at the lowest price. Acalabrutinib is specifically used for the treatment of mantle cell lymphoma (MCL), especially in patients who have already recei...

Acalabrutinib's Impact on Mantle Cell Lymphoma (MCL) Treatment

Healthcare providers play a crucial role in the successful implementation of acalabrutinib therapy for Mantle Cell Lymphoma. theindianpharma.com/blog-post/wh...

#AcalabrutinibImpact #MantleCellLymphoma #MCLTreatment #CancerTherapy